| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Biochemistry and Molecular Biophysics, College of Physicians and Surgeons, Columbia University, New York, NY 10032
Mice lacking the gene for the IL-1R antagonist (IL-1ra) show abnormal development and homeostasis as well as altered responses to infectious and inflammatory stimuli. A reduction in the level of IL-1 signaling, either by deletion of the receptor or increased expression of IL-1ra, does not affect development or homeostasis, but does alter immune responses. In this study we use genetic epistasis to investigate the interdependence of selected genes in the IL-1 family in the regulation of these developmental and immunological processes. Deletion of the gene encoding the type I IL-1R (IL-1RI) is epistatic to deletion of the IL-1ra gene. Therefore, all functions of IL-1ra depend upon the presence of a functional receptor; there is no other target. Similarly, overexpression of the mRNA encoding the secreted form of IL-1ra is epistatic to deletion of the receptor antagonist, leaving the role of the intracellular splice variants of IL-1ra unknown. The abnormal development of IL-1ra-deficient mice is probably due to chronic overstimulation of the proinflammatory pathway via IL-1, but a clear single pathological defect is not apparent. These results support the model that the only essential function of IL-1ra in both health and disease is competitive inhibition of the IL-1RI.
This article has been cited by other articles:
|
|
 |
|
  T. P. Obrenovitch Molecular Physiology of Preconditioning-Induced Brain Tolerance to Ischemia Physiol Rev, January 1, 2008; 88(1): 211 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Crow, S. Song, J. W. Semple, J. Freedman, and A. H. Lazarus A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg? Blood, January 1, 2007; 109(1): 155 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Somm, E. Henrichot, A. Pernin, C. E. Juge-Aubry, P. Muzzin, J.-M. Dayer, M. J.H. Nicklin, and C. A. Meier Decreased Fat Mass in Interleukin-1 Receptor Antagonist-Deficient Mice: Impact on Adipogenesis, Food Intake, and Energy Expenditure Diabetes, December 1, 2005; 54(12): 3503 - 3509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shepherd and M. J.H. Nicklin Elastic-Vessel Arteritis in Interleukin-1 Receptor Antagonist-Deficient Mice Involves Effector Th1 Cells and Requires Interleukin-1 Receptor Circulation, June 14, 2005; 111(23): 3135 - 3140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ashare, L. S. Powers, N. S. Butler, K. C. Doerschug, M. M. Monick, and G. W. Hunninghake Anti-inflammatory response is associated with mortality and severity of infection in sepsis Am J Physiol Lung Cell Mol Physiol, April 1, 2005; 288(4): L633 - L640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y M J Lin, H C Yang, T J Lai, C S J Fann, and H S Sun Receptor mediated effect of serotonergic transmission in patients with bipolar affective disorder J. Med. Genet., October 1, 2003; 40(10): 781 - 786. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Liu, A. A. Roberts, and T. Ganz By IL-1 Signaling, Monocyte-Derived Cells Dramatically Enhance the Epidermal Antimicrobial Response to Lipopolysaccharide J. Immunol., January 1, 2003; 170(1): 575 - 580. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
